a study on Achondroplasia
This is a Phase 2, open-label, sequential cohort dose-escalation study of BMN 111 in children with achondroplasia. The primary objective is to assess the safety and tolerability of daily BMN 111 administered to children with achondroplasia.
A Phase 2, Open-label, Sequential Cohort Dose-escalation Study of BMN 111 in Children With Achondroplasia
Achondroplasia Dwarfism Bone Diseases, Developmental Bone Diseases Natriuretic Peptide, C-Type
Open to people ages 5 years to 14 years
Additional inclusion Criteria Optional, Open-label Extension Phase:
Additional Exclusion Criteria for Optional, Open-label Extension Phase:
© 2017 The Regents of the University of California